Greece - Buy the Di...
Health Care: Drugs
CytRx Corporation (CYTR: NASDAQ)
$0.36 0.00 | 1.43%
02/09/12 - 03:59 PM ET
1.24M / 909.40K
Vol / Avg. Vol:0.35 / 0.35
Open / Prev. Close:0.34 - 0.36
Today's Range:0.24 - 1.06
52 Wk Range:25.00%
Performance YTD:TheStreet Rating:
Portfolios with CYTR
- Portfolio NameUser Type
- Contributor5 Stocks Under-$10 Setting ...
- UserHope For The Best
- Userrick epple
- ContributorBarron's Research Reports 1...
- UserNat's
- UserHi Potential
- Usernewintrade Portfolio 1
- Usersteveandvickie Portfolio 1
- Useractive-jrd
- UserRAPTOR SPRTD-0910081159
Latest CYTR Headlines from TheStreet
- 5 Stocks Under $10 With Big Upside Potential 11.18.11 | 06:11 am
- SeaChange, Tenet: Early Volume Plays 12.03.09 | 08:12 am
- CytRx: FDA Lifts 2-year Hold On Arimoclomol Tests 12.02.09 | 09:12 am
- Correction: CytRx FDA Letter 09.09.09 | 04:09 pm
- CytRx Expects To File FDA Response In 4Q 09.08.09 | 10:09 am
- CytRx Rises On Preclinical Data For Stroke Drug 08.24.09 | 01:08 pm
- Movers Roundup: Massey Energy, MannKind 06.08.09 | 02:06 pm
- CytRx Rises On Analyst's 'Outperform' Rating 06.08.09 | 01:06 pm
- Biotech Notebook: Nastech, Amgen, PDL BioPharma 11.15.07 | 04:11 pm
- Wednesday's Health Winners & Losers 11.14.07 | 03:11 pm
Press Releases for CYTR
- CytRx To Present At BIO CEO & Investor Conference - Business Wire 02.06.12 | 08:02 am
- CytRx Initiates International Phase 2b Clinical Trial With INNO-206 In Advanced Soft Tissue Sarcoma - Business Wire 12.22.11 | 08:12 am
- CytRx Announces The Presentation Of Favorable Phase 2 Clinical Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia At ASH Conference - Business Wire 12.12.11 | 08:12 am
- CytRx Reports Third Quarter 2011 Financial Results - Business Wire 11.08.11 | 08:11 am
- CytRx To Present At Lazard Capital Markets 8th Annual Healthcare Conference - Business Wire 11.07.11 | 08:11 am
- CytRx Announces Favorable Initial Results From Its Ongoing Phase 1b/2 Clinical Trial In Patients With Soft Tissue Sarcomas - Business Wire 10.31.11 | 08:10 am
- CytRx’s ENABLE Phase 2 Trial Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia To Be Presented At The Prestigious 53rd Annual ASH Meeting - Business Wire 10.04.11 | 08:10 am
- CytRx To Substantially Increase Patient Enrollment In INNO-206 Phase 1b/2 Clinical Trial Principally In Patients With Soft Tissue Sarcomas - Business Wire 09.26.11 | 08:09 am
- CytRx To Present At The Rodman & Renshaw 13th Annual Healthcare Conference - Business Wire 09.06.11 | 08:09 am
- CytRx President And CEO Steven Kriegsman And CMO Dr. Daniel Levitt Discuss Company Advantages And Oncology Clinical Pipeline Attributes In OncLive Interview - Business Wire 08.22.11 | 08:08 am
Partner Headlines for CYTR
- Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog - Zacks 01.09.12 | 07:01 am
- Why CytRx Corporation Is Still A Big Biotech 'If' Play - Seeking Alpha 12.14.11 | 09:12 am
- CytRx Is Poised For Growth - Analyst Blog - Zacks 08.13.11 | 12:08 am
- CytRx Reports 2Q 2011 Results - Analyst Blog - Zacks 08.12.11 | 06:08 pm
- As the Market Dips, It's Time to Look for Biotech Sector Deals - Seeking Alpha 06.12.11 | 09:06 am
- CytRx Completes Sale of Molecular Chaperone Assets - Analyst Blog - Zacks 05.17.11 | 09:05 am
- Company News for April 29, 2011 - Corporate Summary - Zacks 04.29.11 | 10:04 am
- Stocks Mixed at Session's Half on Slowing Q1 Economy; Crude Futures Advance - NASDAQ 04.28.11 | 04:04 pm
- Mid-Day Update: Stocks Mixed as GDP Data Weighs; Jobless Claims Rise - NASDAQ 04.28.11 | 04:04 pm
- China Analyst: 10 Pharma Stocks With Highest Growth Potential - Seeking Alpha 10.08.10 | 06:10 am
